{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:direct-vasodilators-hydralazine-minoxidil",
  "owner": "cardio",
  "kind": "drug",
  "slug": "direct-vasodilators-hydralazine-minoxidil",
  "name": "Direct vasodilators (hydralazine, minoxidil)",
  "aliases": [
    "Direct vasodilators",
    "Arteriolar vasodilator"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Medicines that lower blood pressure by relaxing the muscle in blood vessel walls. The US label read for hydralazine lists essential hypertension. The label read for minoxidil limits its use to high blood pressure that is symptomatic or damaging organs and that is not manageable with maximum doses of a diuretic plus two other blood pressure medicines, and it carries a boxed warning about serious adverse effects.",
  "summary_technical": "Class page. MeSH descriptor D014665 (Vasodilator Agents, last updated 2020-05-27) is a broad match, because it covers every medicine used to dilate blood vessels and not only these two. Two US labels were read: hydralazine hydrochloride tablets (application ANDA086242, effective 2025-12-10 in openFDA) and minoxidil tablets (application ANDA072708, effective 2026-01-21 in openFDA; established pharmacologic class Arteriolar Vasodilator). Both are generic labels, not the original brand. The hydralazine label says its mechanism is not fully understood. A separate claim records the minoxidil boxed warning. The label texts read state no age range for their uses. This page gives no dose, no trial result and no guideline statement. Medicines of the group that have their own pages are filed under it.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-09",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D014665",
      "normalized_value": "D014665",
      "match": "broad",
      "version": "MeSH linked-data descriptor record fetched on 2026-11-09, lastUpdated 2020-05-27; the record states no yearly MeSH release",
      "label": "Vasodilator Agents",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels"
      ],
      "condition-area": [
        "hypertension"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "The hydralazine label says the precise mechanism is not fully understood and that it lowers blood pressure through a peripheral vasodilating effect, a direct relaxation of vascular smooth muscle. The minoxidil label calls minoxidil a direct acting peripheral vasodilator."
  },
  "content_digest": "e7eebdace104acaa41f548a3d6498183e959a17d1c76174d3fa7dca63899f0aa",
  "review": {
    "content_digest": "e7eebdace104acaa41f548a3d6498183e959a17d1c76174d3fa7dca63899f0aa",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-minoxidil-label-boxed-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:direct-vasodilators-hydralazine-minoxidil",
      "category": "safety",
      "statement": "The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) carries a boxed warning. It says the tablets contain a powerful antihypertensive agent that may produce serious adverse effects, and that minoxidil can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated.",
      "context": {
        "id": "cardio:ctx-fda-minoxidil-label-boxed-warning-us",
        "label": "People treated with minoxidil tablets for hypertension, as described in the boxed warning of a US label",
        "recipient": "unknown",
        "population": "Patients treated with minoxidil tablets, as the boxed warning of the label describes the risk.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (US drug label)",
        "life_stage_note": "Not stated in the passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients treated with minoxidil tablets for hypertension"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records two statements of the label's boxed warning only. The boxed warning also lists other effects and steps for managing treatment; they are not repeated here. The label read is a generic label, not the original brand, and states no age range. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-09",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0]",
          "applicability_note": "Serious adverse effects, pericardial effusion and angina.",
          "snapshot": {
            "id": "cardio:openfda-label-minoxidil-avkare-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:47Z",
            "content_hash": "02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-minoxidil-avkare",
            "source_type": "regulator",
            "title": "openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-minoxidil-avkare.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260121.",
          "snapshot": {
            "id": "cardio:openfda-label-minoxidil-avkare-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:47Z",
            "content_hash": "02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-minoxidil-avkare",
            "source_type": "regulator",
            "title": "openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-minoxidil-avkare.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "4e90b1c6caf15f01fcfa3bc8ff112df7f26e9e4ce83eb7cecee755d3934d2810",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-minoxidil-label-boxed-warning.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-vasodilator-labels-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:direct-vasodilators-hydralazine-minoxidil",
      "category": "descriptive",
      "statement": "Two US generic labels were read. The label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct, and says the medicine apparently lowers blood pressure through a peripheral vasodilating effect, a direct relaxation of vascular smooth muscle. The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) calls the medicine an antihypertensive peripheral vasodilator, and says that because of the potential for serious adverse effects it is indicated only for hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. MeSH describes vasodilator agents as drugs used to cause dilation of the blood vessels.",
      "context": {
        "id": "cardio:ctx-fda-vasodilator-labels-us",
        "label": "People with hypertension, for minoxidil only hypertension that is symptomatic or damaging organs and not manageable with maximum doses of a diuretic plus two other drugs, as described in two US labels",
        "recipient": "unknown",
        "population": "Patients described in the indications sections of the two labels: patients with essential hypertension (hydralazine), and patients with hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil).",
        "care_setting": "Prescription medicine, as described in the US labels",
        "geography": "United States (US drug labels)",
        "life_stage_note": "Not stated in the passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Essential hypertension (hydralazine label)",
            "Hypertension that is symptomatic or associated with target organ damage and not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil label)"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what two US generic labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. Neither label is the original brand. The labels read state no age range. The minoxidil boxed warning is recorded in a separate claim. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-09",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], INDICATIONS AND USAGE",
          "applicability_note": "Hydralazine: essential hypertension.",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].clinical_pharmacology[0], CLINICAL PHARMACOLOGY",
          "applicability_note": "Hydralazine: peripheral vasodilating effect.",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20251210.",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], INDICATIONS AND USAGE",
          "applicability_note": "Minoxidil: limited use in hypertension.",
          "snapshot": {
            "id": "cardio:openfda-label-minoxidil-avkare-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:47Z",
            "content_hash": "02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-minoxidil-avkare",
            "source_type": "regulator",
            "title": "openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-minoxidil-avkare.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].description[0], DESCRIPTION",
          "applicability_note": "Minoxidil: antihypertensive peripheral vasodilator.",
          "snapshot": {
            "id": "cardio:openfda-label-minoxidil-avkare-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:47Z",
            "content_hash": "02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-minoxidil-avkare",
            "source_type": "regulator",
            "title": "openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-minoxidil-avkare.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260121.",
          "snapshot": {
            "id": "cardio:openfda-label-minoxidil-avkare-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:47Z",
            "content_hash": "02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-minoxidil-avkare",
            "source_type": "regulator",
            "title": "openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-minoxidil-avkare.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "scopeNote.@value",
          "applicability_note": "MeSH scope note: what vasodilator agents are.",
          "snapshot": {
            "id": "cardio:mesh-scope-d014665-2026-11-09",
            "retrieved_at": "2026-11-09T13:15:50Z",
            "content_hash": "c3651b01270284b23f245ca88fd1185739a299f3cecd5a0f220667884e135043",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:mesh-scope-d014665",
            "source_type": "dataset",
            "title": "MeSH scope note for descriptor D014665 (Vasodilator Agents)",
            "canonical_url": "https://id.nlm.nih.gov/mesh/M0022559",
            "identifiers": [
              {
                "scheme": "mesh",
                "value": "M0022559",
                "normalized_value": "M0022559",
                "match": "exact",
                "version": "id.nlm.nih.gov linked data, preferred concept of descriptor D014665, retrieved 2026-11-09",
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. National Library of Medicine",
            "edition": "MeSH linked-data record of the preferred concept M0022559 of descriptor D014665, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.",
            "reuse_basis": "The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed at research/snapshots/w4k03-meshc-M0022559.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "71a84f72e9c7bea027a5ef1fc4b9cf09a696e9f7013ee29fb409a52f6263e877",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-vasodilator-labels-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "Two US labels list treating high blood pressure as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-vasodilator-labels-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Blood pressure lowering medicine, the care strategy",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:bp-lowering-medicine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:hydralazine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-5470-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/direct-vasodilators-hydralazine-minoxidil/",
  "context_path": "api/v1/context/cardio--direct-vasodilators-hydralazine-minoxidil.md"
}
